Elly Gerald Stoica

Array ( [id] => 16665297 [patent_doc_number] => 10934532 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-02 [patent_title] => ALK4.ActRIIB heteromultimers [patent_app_type] => utility [patent_app_number] => 15/726255 [patent_app_country] => US [patent_app_date] => 2017-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 18 [patent_no_of_words] => 64022 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15726255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15527223 [patent_doc_number] => 20200055917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => CHIMERIC ENGULFMENT RECEPTOR MOLECULES [patent_app_type] => utility [patent_app_number] => 16/334224 [patent_app_country] => US [patent_app_date] => 2017-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16334224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12118845 [patent_doc_number] => 20180002430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'ANTI HUMAN INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN (IL1 RAP) ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/707593 [patent_app_country] => US [patent_app_date] => 2017-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 26158 [patent_no_of_claims] => 118 [patent_no_of_ind_claims] => 43 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15707593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14357593 [patent_doc_number] => 10300076 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-28 [patent_title] => Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists [patent_app_type] => utility [patent_app_number] => 15/704726 [patent_app_country] => US [patent_app_date] => 2017-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 15556 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15704726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16673148 [patent_doc_number] => 20210061911 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies [patent_app_type] => utility [patent_app_number] => 16/644789 [patent_app_country] => US [patent_app_date] => 2017-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10203 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16644789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14581351 [patent_doc_number] => 20190218284 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => METHODS OF TREATING EOSINOPHILIC GASTROINTESTINAL DISEASES [patent_app_type] => utility [patent_app_number] => 16/327045 [patent_app_country] => US [patent_app_date] => 2017-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8157 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16327045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13699951 [patent_doc_number] => 20170360930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => VEGF ANTAGONIST FORMULATIONS [patent_app_type] => utility [patent_app_number] => 15/692893 [patent_app_country] => US [patent_app_date] => 2017-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5193 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15692893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13702747 [patent_doc_number] => 20170362328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => METHOD OF TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIA [patent_app_type] => utility [patent_app_number] => 15/690826 [patent_app_country] => US [patent_app_date] => 2017-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8291 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15690826 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12117315 [patent_doc_number] => 20180000900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/684168 [patent_app_country] => US [patent_app_date] => 2017-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 45166 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 28 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15684168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14531741 [patent_doc_number] => 20190201491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => BOVINE FIBROBLAST GROWTH FACTOR 21 AND KETOSIS IN DAIRY CATTLE [patent_app_type] => utility [patent_app_number] => 16/325345 [patent_app_country] => US [patent_app_date] => 2017-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6409 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16325345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17080524 [patent_doc_number] => 20210275530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => TREATMENT CANCERS USING A COMBINATION COMPRISING BTK INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/326467 [patent_app_country] => US [patent_app_date] => 2017-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16712 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 465 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16326467 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14005613 [patent_doc_number] => 10221244 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-05 [patent_title] => Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer [patent_app_type] => utility [patent_app_number] => 15/680664 [patent_app_country] => US [patent_app_date] => 2017-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 63538 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 340 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15680664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467793 [patent_doc_number] => 20190185539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => TREATMENT AND DIAGNOSIS OF CANCER OR INFECTIOUS DISEASE USING RECOGNITION MECHANISM OF T CELL RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/323365 [patent_app_country] => US [patent_app_date] => 2017-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17698 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16323365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12157367 [patent_doc_number] => 20180028632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'METHOD OF TREATING TUMORS WITH NK AND NKT CELLS EXPRESSING ANTI-SSEA4 CHIMERIC ANTIGEN RECEPTORS' [patent_app_type] => utility [patent_app_number] => 15/664129 [patent_app_country] => US [patent_app_date] => 2017-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2889 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15664129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12157369 [patent_doc_number] => 20180028634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'METHOD FOR PROLONGING AND ENHANCING ANTI-TUMOR VACCINE RESPONSE' [patent_app_type] => utility [patent_app_number] => 15/664197 [patent_app_country] => US [patent_app_date] => 2017-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3014 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15664197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12157365 [patent_doc_number] => 20180028630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'COMPOSITIONS AND METHODS FOR THERAPEUTIC ANTI-CANCER VACCINATION' [patent_app_type] => utility [patent_app_number] => 15/664065 [patent_app_country] => US [patent_app_date] => 2017-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2063 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15664065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17921611 [patent_doc_number] => 11464832 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => Composition for treating or sensitizing interferon beta resistant cancer disease comprising cFLIP siRNA [patent_app_type] => utility [patent_app_number] => 16/321409 [patent_app_country] => US [patent_app_date] => 2017-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 10375 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16321409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12022261 [patent_doc_number] => 20170312360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/655220 [patent_app_country] => US [patent_app_date] => 2017-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9196 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15655220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17937100 [patent_doc_number] => 11471532 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Methods for treatment of [patent_app_type] => utility [patent_app_number] => 16/317753 [patent_app_country] => US [patent_app_date] => 2017-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 13 [patent_no_of_words] => 27015 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 196 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16317753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12808687 [patent_doc_number] => 20180161399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => TREATMENT OF CANCER WITH IMMUNE STIMULATORS [patent_app_type] => utility [patent_app_number] => 15/641550 [patent_app_country] => US [patent_app_date] => 2017-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19204 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15641550 [rel_patent_id] =>[rel_patent_doc_number] =>)